By Daniel Sabet · Cannabis CFO & Financial Advisor, GreenGrowth CPAs · 280E, Tax Strategy & Growth Planning · Los Angeles, CA | Published June 2026 | Cannabis Tax
Cannabis rescheduling 2026 took an unexpected turn when the DEA announced the participant list for its upcoming hearing on broader marijuana rescheduling. According to industry reports, every selected participant appears to oppose cannabis reform, while organizations supporting rescheduling were reportedly excluded. In GreenGrowth’s experience advising cannabis operators across California, New York, New Jersey, and Minnesota, this kind of procedural headline creates real anxiety but rarely changes the underlying math. Cannabis rescheduling 2026 remains a multi-step federal process, and the hearing beginning June 29th is one step among many that will determine the outcome.
Quick Answer
The DEA scheduled a hearing beginning June 29th, 2026 to consider whether marijuana more broadly should move to Schedule III, but reports indicate every invited participant opposes cannabis reform while pro-rescheduling voices were excluded. This raises real concerns about the hearing’s fairness. However, a hearing participant list is not a final rule. The ultimate outcome depends on scientific evidence, legal analysis, and prior agency findings — including the Department of Health and Human Services recommendation that marijuana has accepted medical use. Operators should avoid major strategic decisions based on this headline alone and instead focus on financial preparation that works regardless of the outcome.
Cannabis Rescheduling 2026 — At a Glance
- What it is: A DEA administrative hearing, beginning June 29th, 2026, to consider whether marijuana broadly should move from Schedule I to Schedule III under federal law
- Who it applies to: Adult-use and recreational cannabis operators — medical marijuana operators were already addressed under a separate April 2026 federal order
- Key controversy: Reports indicate every selected hearing participant opposes broader cannabis reform, while pro-rescheduling organizations were reportedly excluded from the process
- Primary stake: Section 280E — the federal tax provision that currently blocks most cannabis businesses from deducting payroll, rent, marketing, and other ordinary expenses
- What it is not: A final decision — the hearing is one input among scientific evidence, legal analysis, and prior agency findings that will shape the eventual outcome
- GreenGrowth’s role: CFO and tax team helps operators build financial systems and scenario plans that perform well whether rescheduling happens quickly, slowly, or in phases
Related resource: GreenGrowth Cannabis Industry Tax & CFO Services →
What Is Actually Being Decided in the DEA Rescheduling Hearing?
In April 2026, the federal government moved certain state-licensed medical marijuana activities and FDA-approved marijuana products from Schedule I to Schedule III. That order addressed medical operators specifically. Broader recreational cannabis activity remained unresolved, which is why the DEA scheduled a separate hearing beginning June 29th, 2026, to consider whether marijuana more broadly should move to Schedule III.
Why Schedule III Treatment Would Be Transformational
The biggest reason this hearing matters is Section 280E. Most cannabis businesses currently cannot deduct ordinary business expenses, because they are treated as Schedule I operators under federal tax law. Payroll, marketing, professional fees, rent, insurance, and interest expense are largely limited or disallowed under current rules. That treatment creates substantial tax burdens that consume cash flow and limit growth for otherwise healthy businesses.
In GreenGrowth’s experience, some operators generate strong revenue yet struggle with profitability purely because of federal tax treatment. Other businesses would become dramatically more valuable if that tax burden were reduced. Consequently, every development in the rescheduling process draws intense attention from operators, investors, and advisors across the industry.
Who This Article Is For
- You operate an adult-use or recreational cannabis business and want to understand what the June 29th hearing does and does not decide
- You are evaluating an investment or acquisition in cannabis and need to separate hearing headlines from the actual regulatory timeline
- You are concerned the hearing participant controversy signals rescheduling will fail, and want a clearer picture of how the process actually works
- You want to know what to do operationally while the rescheduling process continues, rather than simply waiting for an outcome
The Hearing Participant Controversy, Explained
The controversy surrounding this hearing centers on who was invited to participate. According to reports, the DEA selected organizations such as Smart Approaches to Marijuana, certain state government representatives, law enforcement-related groups, and other individuals who have historically opposed cannabis reform. Supporters of broader rescheduling and legalization were reportedly excluded from the process entirely.
Why a One-Sided Participant List Doesn’t Decide the Outcome
Whether this selection ultimately affects the result remains uncertain. Administrative hearings are only one component of a much larger federal decision-making process. Scientific evidence, legal analysis, agency findings, public comments, and political considerations all play a role in the eventual outcome — not just testimony heard during the hearing itself.
Notably, the Department of Health and Human Services previously concluded that marijuana has accepted medical use and recommended movement to Schedule III. That recommendation became one of the key foundations supporting the broader rescheduling process. A skewed hearing roster does not erase that existing scientific record.
▶ Benchmark: Headline vs Final Outcome
A Hearing Participant List
- Procedural development
- Generates headlines and market reaction
- Reflects who was invited to testify
- Does not itself change federal law
A Final Federal Rule
- Legally binding outcome
- Incorporates scientific and legal review
- Reflects the full administrative record
- Actually changes business and tax treatment
💬 The Conversation Worth Having
Ask your CFO or tax advisor: “If the rescheduling hearing produces no change by year-end, does our financial plan still work?” If the honest answer depends on a favorable outcome, the business is speculating, not planning. Operators who can answer yes regardless of the hearing’s result are the ones positioned to benefit whenever reform actually arrives.
Does your financial plan hold up regardless of how the hearing turns out?
Request a Rescheduling Readiness Review →Cannabis Rescheduling 2026: What Operators Should Do Right Now
The operators who succeed through regulatory transitions are usually the ones who focus on preparation rather than speculation. They build strong financial systems, improve compliance, and strengthen operations regardless of what the hearing produces. Four practical steps apply right now.
Stay Informed, Stay Disciplined
The rescheduling process is moving, but it remains far from finished. Tracking developments matters. However, reacting to every headline with a strategic pivot creates its own risk. Discipline means separating genuine regulatory milestones from procedural noise.
Plan for Multiple Scenarios
Prepare for a world where broader rescheduling happens on schedule. Prepare separately for a world where it takes longer than expected, and for one where federal reform arrives in phases rather than all at once. Each scenario carries different tax and cash flow implications worth modeling now, before any final rule appears.
Focus on Operational Efficiency
The businesses that survive uncertainty are rarely the ones making the boldest predictions. Instead, they are the operators managing cash flow tightly, controlling expenses deliberately, and maintaining strong compliance systems that hold up under scrutiny no matter how federal policy evolves.
Remember That Reform Is a Marathon
The cannabis industry has already endured years of regulatory delays, litigation, and political battles. This hearing is another chapter in that story, not the final one. Operators who remain focused on fundamentals while others focus on headlines will be in the strongest position when the dust eventually settles.
Related resource: GreenGrowth Accounting & Financial Services for Cannabis Operators →
Does the Hearing Participant Controversy Mean Rescheduling Will Fail?
No — a one-sided hearing participant list does not mean broader cannabis rescheduling will fail, though it does raise legitimate fairness concerns worth monitoring. The hearing is only one input into a federal decision that also depends on scientific evidence, legal analysis, prior agency findings, and public comment.
The Department of Health and Human Services has already recommended Schedule III treatment based on accepted medical use, and that recommendation does not disappear because of who testified at one hearing. Operators should treat this development as a reason for continued attention, not a reason for panic or premature strategic pivots.
KEY TAKEAWAYS
- › Cannabis rescheduling 2026 enters a new phase June 29th when the DEA hearing on broader marijuana rescheduling begins, with reports indicating every selected participant opposes reform
- › Section 280E remains the single biggest financial reason this hearing matters — Schedule III treatment could allow operators to deduct payroll, rent, marketing, and other ordinary expenses
- › A skewed hearing participant list raises fairness concerns but does not by itself determine the final outcome, which depends on scientific evidence and prior agency findings as well
- › Operators should plan for multiple scenarios — fast rescheduling, delayed rescheduling, and phased reform — rather than building a financial plan around a single predicted outcome
- › Operators who focus on cash flow discipline, compliance strength, and operational efficiency consistently outperform those who base strategy on regulatory predictions
Frequently Asked Questions
The DEA scheduled a hearing beginning June 29th, 2026, and continuing through mid-July, to consider whether marijuana more broadly should move from Schedule I to Schedule III under federal law. This hearing addresses recreational and adult-use cannabis activity specifically, since a separate April 2026 federal order already moved certain state-licensed medical marijuana businesses to Schedule III.
The hearing is an administrative process that gathers testimony and evidence, but it does not itself issue a final rule. The eventual outcome depends on a combination of hearing testimony, scientific evidence, legal analysis, and prior agency findings, including a Department of Health and Human Services recommendation that marijuana has accepted medical use.
The hearing participant list is controversial because, according to reports, every selected participant appears to oppose broader cannabis reform. Organizations such as Smart Approaches to Marijuana, certain state government representatives, and law enforcement-related groups were reportedly invited, while organizations and advocates that support rescheduling were excluded from the process.
This selection has created significant concern throughout the cannabis industry, since many operators expected the hearing to include a broad range of viewpoints from both supporters and opponents of rescheduling. Whether the participant selection ultimately affects the final outcome remains uncertain, since administrative hearings are only one component of a much larger federal decision-making process.
No, a one-sided hearing participant list does not necessarily mean broader cannabis rescheduling will fail. The final regulatory outcome depends on more than hearing testimony alone — it incorporates scientific evidence, legal analysis, agency findings, and public comment submitted through the broader administrative process.
The Department of Health and Human Services has already concluded that marijuana has accepted medical use and recommended movement to Schedule III, a finding that remains part of the administrative record regardless of who testifies at this particular hearing. Operators should treat the participant controversy as a reason for continued monitoring, not as confirmation that reform has failed.
Section 280E matters because it currently prevents most cannabis businesses from deducting ordinary business expenses, including payroll, marketing, professional fees, rent, insurance, and interest expense, since they are treated as Schedule I operators under federal tax law. That treatment creates substantial tax burdens that consume cash flow and limit growth even for businesses with strong revenue.
If broader rescheduling moves marijuana to Schedule III, the same relief already available to qualifying medical operators under the April 2026 order could extend to adult-use and recreational operators as well. For many businesses, the elimination or reduction of 280E exposure would have a greater financial impact than nearly any other regulatory change available to the cannabis industry.
Generally, no. Operators should avoid making major strategic decisions based solely on headlines surrounding the hearing participants, since markets often overreact to procedural developments that do not themselves change federal law. A hearing participant list generates headlines, but only a final federal rule actually changes business and tax treatment.
The operators who succeed through regulatory transitions typically focus on preparation rather than speculation. That means building strong financial systems, improving compliance, and strengthening operations in ways that perform well under multiple possible outcomes, rather than betting the business on a specific predicted timeline.
Cannabis operators should take four practical steps while the rescheduling process continues. First, stay informed but stay disciplined, separating genuine regulatory milestones from procedural noise. Second, plan for multiple scenarios, including fast rescheduling, delayed rescheduling, and phased federal reform, each with different financial implications worth modeling in advance.
Third, focus on operational efficiency by managing cash flow, controlling expenses, and maintaining strong compliance systems regardless of regulatory timing. Fourth, treat federal reform as a marathon rather than a sprint, recognizing that the cannabis industry has already endured years of delays and political battles, with this hearing representing another chapter rather than a final resolution.
|
Find out whether your business is positioned to benefit from cannabis rescheduling, whenever it arrives GreenGrowth’s Cannabis Tax team builds scenario-based financial plans, models 280E exposure under multiple regulatory outcomes, and strengthens the compliance systems that protect your business regardless of how long the rescheduling process takes. Request a Rescheduling Readiness Review →Learn About Our Services → |
KEY NUMBERS June 29, 2026
Start date of the DEA hearing on broader cannabis rescheduling
Mid-July
Expected conclusion of the hearing process
April 2026
When medical marijuana businesses already moved to Schedule III under a separate order
280E
The tax code section at the center of the entire rescheduling debate
3 Scenarios
Fast, delayed, and phased rescheduling — operators should plan for all three
|
GreenGrowth’s team helps cannabis operators prepare for rescheduling under any scenario
GreenGrowth’s Cannabis Tax team builds the financial systems and scenario plans that perform well whether rescheduling happens quickly, slowly, or in phases.
Request a Review →GreenGrowth CPAs · Cannabis Tax Team
